Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Global Pharmaceutical and Life Sciences Real World Evidence Market Report 2021: Distribution by Applications, Real World Data Sources, Key Therapeutic Areas and Geography

Published

on

Dublin, April 29, 2021 (GLOBE NEWSWIRE) — The “Pharmaceutical and Life Sciences Real World Evidence (2nd Edition), 2021-2030: Distribution by Applications, Real World Data Sources, Key Therapeutic Areas and Geography” report has been added to ResearchAndMarkets.com’s offering.

Drug discovery and development is a complex and time intensive process that requires a significant amount of resources and capital investments (~USD 2.6 billion). In fact, on an average, the journey from establishment of initial proof-of-concept to product launch, takes around 10-12 years. Moreover, regulatory approval is dependent on the results of randomized clinical trials (RCTs), which are estimated to account for a staggering 40% of the pharmaceutical industry’s budget in the US. It is also well known that clinical research is fraught with various other challenges, including inefficiencies in medical data management and processing, unforeseen delays, risk of failure / study termination and several patient recruitment and retention-related concerns.

Further, since such trials are conducted under controlled conditions and involve a fairly homogenous patient population, there are chances that, post commercial launch, approved products fail to perform as expected. In this context, the application of insights from real world data, accrued from past trials, has been demonstrated to have the potential to save up to USD 1 billion per year. In fact, real world evidence can actually complement results from controlled RCTs, thereby, validating the therapeutic potential of a new chemical / biological entity.

In December 2016, after the 21st Century Cures Act was passed, the United States Food and Drug Administration (USFDA) began considering the application of real world evidence in healthcare decision-making. Ever since, pharmaceutical companies and health economists have developed advanced tools and analytical algorithms to mine pharmaceutical big data, in order to better understand the clinical value of product candidates targeting some of the rarest medical conditions. Presently, big pharmaceutical companies are estimated to spend nearly USD 20 million on an annual basis, on generating real world evidence to support their respective clinical development programs. Over time, insights from real world data have not only influenced product approval-related decisions, but also helped convince insurance provider / payers into offering reimbursement for new drugs / therapies. The growing adoption of artificial intelligence and machine learning in big data analysis, is anticipated to better inform future drug discovery initiatives, thereby, reducing the risk of product failure. The adoption of real world evidence in healthcare decision making is projected to grow substantially as the healthcare industry shifts towards the personalized medicine.

The report features an extensive study of the current market landscape and future potential of the industry players that are engaged in offering real world data / analytics / services to the pharmaceutical and life sciences industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

The USD 4.5 billion (by 2030) financial opportunity within the real world evidence market has been analyzed across the following segments:

  • Type of Application
  • Types of Real World Data Sources
  • Therapeutic Area
  • Geography

Companies Mentioned

  • AbbVie
  • Acceliant
  • Accenture
  • Accsight
  • Advera Health Analytics
  • Aetion
  • AG Mednet
  • Aixial
  • Allergan
  • Allscripts
  • Alpha MD
  • AMA Innovation Lab
  • AstraZeneca
  • ASUS Life
  • ATAI Life Sciences
  • Atrium Health
  • Axonal-Biostatem
  • Axtria
  • Bayer
  • BC Platforms
  • Bio Valley
  • Bioserv
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Bristol-Myers Squibb
  • CB Insights
  • Celeri Health
  • Cisiv
  • CitiusTech
  • CK Aspire
  • Clarivate Analytics
  • Cleveland Clinic
  • Clinerion
  • Clinical Trial EndPoint
  • Clinigen Group
  • Cloudera
  • CloudMoyo
  • Cluell
  • Cognizant
  • conferenceseries.com
  • Covance
  • Custodix
  • Cytel
  • D Cube Analytics
  • Daiichi Sankyo
  • Data2Life
  • Databricks
  • Datavant
  • DCC
  • DHIS2
  • DIGIPHARM
  • DuPage Medical Group
  • eClinical Forum
  • Econcare
  • Eli Lilly
  • Elligo Health Research
  • Ephicacy
  • EPID Research
  • ESiOR
  • EUCROF
  • EVERSANA
  • Evex Medical
  • Evidera
  • Evidilya
  • Excelra
  • ExL Events
  • eyeforpharma
  • Flatiron Health
  • Fuzzy Logix
  • Gate2Biotech
  • Genentech
  • Genospace
  • GlaxoSmithKline
  • GNS Healthcare
  • Graticule
  • GSK
  • Harvard Medical School
  • Healiant
  • IBC Asia
  • IBM Watson Health (IBM)
  • iClusion
  • Idorsia
  • Indegene
  • Infosys
  • Ingress Health
  • Innovation Enterprise
  • Inovalon
  • Insight Pharma Services
  • IntrinsiQ Specialty Solutions
  • IQVIA
  • Janssen
  • JDRF
  • Johaus Global
  • Johns Hopkins University
  • Kaiku Health
  • Kaiser Permanente
  • LynxCare
  • M2Gen
  • M2S
  • MA Provider
  • MakroCare
  • MAP BioPharma
  • marcus evans
  • MarkLogic
  • Medialis
  • Medpace
  • MedSoft
  • Medstreaming
  • Medtronic
  • Merck
  • Metaforms
  • Model Answers
  • Novartis
  • Novo Nordisk
  • Numerus
  • O4 Research
  • Omega CRO
  • OncoStats
  • OPEN Health
  • Optra Systems
  • OptumInsight
  • Opyl
  • Oracle
  • OrbitalRX
  • Oriola
  • Pfizer
  • pH Associates
  • phUSE
  • PotentiaMED
  • PRA Health Sciences
  • Premier
  • Provisio
  • Public Health England
  • Qlik
  • Quantify Research
  • Quantzig
  • Raven Biosciences
  • Real Consulting Data
  • REAL Europe
  • Roam
  • Roche
  • RTI Health Solutions
  • RWE Genesys
  • RxAnte
  • S3 Connected Health
  • SAS
  • Savana
  • Sciformix
  • Self Care Catalysts
  • Semicrol
  • SerenaGroup
  • SHYFT Analytics
  • SmartAnalyst
  • SMi Group
  • SQN Clinical
  • Stanford University
  • StatFinn
  • Strategy Institute
  • SVMPharma
  • Syapse
  • Syneos Health
  • Synergus
  • Syntel
  • Takeda Pharmaceuticals
  • Talking Medicines
  • Talosix
  • Target RWE
  • Techtrials International
  • Tempus
  • TFS
  • TriNetX
  • Trinity Industries
  • T-Systems
  • United BioSource (UBC)
  • Validic
  • Verantos
  • Verily Life Sciences
  • Vestrum Health
  • Vitaccess
  • Wipro
  • Xcenda
  • xCures
  • Yale University
  • Zeblok
  • ZEINCRO
  • Zem Solutions
  • Zephyr Health

For more information about this report visit https://www.researchandmarkets.com/r/8kdnqb

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

VIVOTEK Launches Successful Make Tomorrow Easier, Today! Vision During ISC West 2024

Published

on

vivotek-launches-successful-make-tomorrow-easier,-today!-vision-during-isc-west-2024

TAIPEI, April 18, 2024 /PRNewswire/ — VIVOTEK (3454-TW), the global leading IP security solution provider, announces that last week’s 2024 ISC West trade show in Las Vegas was a tremendous success as it unveiled the 2024 theme Make Tomorrow Easier, Today! to partners, attendees, and the media. Make Analytics Easier, Make Cloud Easier, Make Search Easier, and Make Integration Easier were the core essential components of the 2024 theme, and both the booth staff and visitors were very busy discussing its vision throughout the show. This also demonstrates that VIVOTEK’s AI security solutions and cloud-based service VORTEX attracted interests by many customers for their rich versatility in applications.

From the outset, it was clear that this year’s ISC West was going to surpass previous editions. There were more engagements, and these engagements lasted longer than the past as attendees and the media were hyper-focused on VORTEX, its new camera solutions, AI integration, re-launch of VIVOTEK Premium Partner Program, additional technology solutions, and the roll-out of the 2024 theme.
AI has quickly become a priority in the security industry, and it was a focal point of VIVOTEK’s strategy during the show as well. During its many sales and marketing meetings at ISC West, discussions primarily revolved around how to integrate AI into the product lines and software platforms, much to the gratification of its partners who are seeing a quickly growing need for this technology to satisfy their customers’ needs.
As many of its customers may know by now, VIVOTEK recently entered into an integration partnership with Kisi, a modern cloud-based access control solution based in Brooklyn, New York. This partnership aims to secure physical spaces dedicated to providing a seamless and efficient user experience, making Kisi ideally suited as a VIVOTEK partner. During ISC West, VIVOTEK provided Kisi with a station in the booth to perform demonstrations, which proved to be very popular during the show.
Throughout the event, VORTEX remained a central focal point and rapidly gained popularity among partners since its launch. This was evident throughout the show as the VORTEX station was continuously used for strategic demonstrations. As for the theme, attendees commended on how much they liked this year’s booth layout, how the message of “Making Tomorrow Easier, Today” was delivered in every stations, how accessible the staff was in meeting with them, and how much they enjoyed the partner reception party.
VIVOTEK’s commitment to innovation and customer-centric solutions shone brightly at ISC West, as evident in the overwhelmingly positive feedbacks it received from partners, end users, media, and even other exhibit manufacturers. VIVOTEK extends heartfelt thanks to everyone who contributed to making this year’s ISC West a tremendous success. We look forward to making next year’s ISC West even better!
Photo – https://mma.prnewswire.com/media/2390930/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/vivotek-launches-successful-make-tomorrow-easier-today-vision-during-isc-west-2024-302121042.html

Continue Reading

Artificial Intelligence

aiOla’s Speech AI Technology Outperforms OpenAI’s Whisper in Recognizing Jargon

Published

on

aiola’s-speech-ai-technology-outperforms-openai’s-whisper-in-recognizing-jargon

aiOla’s model automates the creation of customized processes and workflows for conducting reports and inspections across industries such as manufacturing, supply chain and logistics, pharma, and more
TEL AVIV, Israel, April 18, 2024 /PRNewswire/ — aiOla, an AI-powered technology that automates business workflows by capturing spoken data, has announced a major milestone in speech recognition. aiOla’s solution, powered by a novel keyword spotting model, has advanced to match human proficiency in understanding industry-specific jargon. The patented AdaKWS model achieved 95% accuracy in keyword spotting, surpassing OpenAI’s industry-leading Whisper model which reached 88% accuracy.

Keyword spotting is an essential aspect of speech recognition that tackles the problem of identifying jargon by detecting predefined words and phrases. “Think about a courier delivery where your package arrives damaged. The courier needs to file a report using specific codes and acronyms that describe the situation — those codes and acronyms are keywords. Industry jargon is everywhere and in many fields, it dominates communication, comprising up to half of workers’ speech,” said aiOla’s CEO and co-founder, Amir Haramaty. “The ability to spot keywords enables automation of everyday processes across a wide range of industries, from filing a parcel damage report to completing a safety inspection in a food manufacturing plant, transforming speech into actions.”
aiOla’s process automation applications can accurately understand speech, jargon and acronyms across over 100 languages, regardless of accents and background noises. aiOla achieves this by combining its state-of-the-art keyword spotting model with a speech recognition model. The onboarding process takes mere hours: clients provide examples of their checklists or forms, and aiOla automatically generates custom language models for the use case. Workers are then able to complete their operations verbally using the aiOla app while keeping their eyes and hands on the equipment. aiOla’s exceptional ability to spot rare industry terms with high accuracy allows the platform to easily distinguish between speech related to work processes and everyday conversation.
The app leverages a proprietary model that was developed by aiOla’s team of scientists to recognize a predefined list of keywords within speech. This enables aiOla’s solution to be instantly adapted to the jargon of any industry without needing to retrain its AI model. On a benchmark of keyword and jargon detection that includes 16 languages, Whisper’s largest model yields 88% accuracy compared to aiOla’s model achieving 95% accuracy. Additionally, in a recent benchmark which is composed of hard-to-detect keywords taken from English language audiobooks, the CED model from a team of Apple researchers yields 92.7% whereas aiOla’s AdaKWS reaches 95.1% accuracy.
“Keyword spotting poses significant challenges due to the scarcity of training data, especially across diverse languages and dialects. It typically requires industry-specific fine-tuning to enable models to recognize jargon not commonly found in everyday speech,” said aiOla’s Chief Scientist, Professor Joseph Keshet. “Our model consistently surpassed the OpenAI Whisper baselines by a significant margin, achieving a substantial improvement compared to the top-performing baseline. Furthermore, our model is far more efficient, using 15x fewer parameters.”
To learn more about aiOla’s technology visit: https://aiola.com
Explore aiOla’s keyword spotting research: https://arxiv.org/pdf/2309.08561.pdf
About aiOla:
aiOla’s patented technology comprehends over 100 languages, and discerns jargon, abbreviations and acronyms, demonstrating a low error rate even in noisy environments. aiOla’s technology converts manual processes in critical industries into data-driven, paperless, AI-powered workflows through cutting-edge speech recognition.

View original content:https://www.prnewswire.co.uk/news-releases/aiolas-speech-ai-technology-outperforms-openais-whisper-in-recognizing-jargon-302121082.html

Continue Reading

Artificial Intelligence

AMN utilises SpaceX’s Starlink Constellation to Connect Rural Villages in Nigeria

Published

on

amn-utilises-spacex’s-starlink-constellation-to-connect-rural-villages-in-nigeria

LONDON, April 18, 2024 /PRNewswire/ — AMN is pleased to announce that the first AMN base station is now live using LEO backhaul from SpaceX’s Starlink. In 2023, AMN announced a commercial agreement to use Starlink, SpaceX’s constellation of satellites in low Earth orbit, to connect AMN’s mobile network base stations with high-speed, low-latency broadband services.

By utilising Starlink terminals to provide low-latency satellite backhaul, we are able to deliver the full capability of AMN’s unique multi-carrier radio access node (the ARN) with 3G and 4G as well as 2G, with ever-increasing amounts of bandwidth and data volumes demanded by subscribers whilst remaining economically sustainable. The LEO backhaul also paves the way for AMN to deliver 5G services, targeted before the end of 2024.
AMN began rolling out rural base stations in Nigeria in 2018, and the company now owns and operates 1600 base stations across the country. Yebu was the first rural community to be connected using AMN’s ubiquitous solar powered base station. The village is located approximately 80km from Abuja, but can take four hours to reach due to road conditions. Yebu is predominantly an agricultural community, with a market offering local farmers the opportunity to sell their goods.
Since connecting the community in November 2018, AMN has processed more than 9 million voice minutes in Yebu, with significant growth in 2022 and 2023 following the BTS upgrade to AMN’s own radio node (ARN). AMN became an OEM for RAN equipment in 2020 following the acquisition of Range Networks, and now operates more than 1200 ARN across Africa and Latin America. The impact of this strategic move is clear in Yebu. In 2023, the site processed almost three times the amount of traffic than it did in 2020.
“Yebu community was left behind and blind but the coming of Africa Mobile Networks in 2018 has made us to achieve a lot of things like police division station, 24 hours solar light and steady communication all over the world. Before then there was nothing like those things listed.” – Salihu, on behalf of the Yebu community
AMN believes that all communities of any significant size should have access to telecommunication services to benefit the population educationally, economically and socially. AMN has deployed over 4000 base stations across Africa and Latin America. Installation of new sites continues throughout 2024 in Nigeria, DRC, Cameroon, Madagascar, Ivory Coast, Benin and Rwanda. At AMN, we appreciate that any solution to close the digital divide must be economically sustainable and offer a service of the same quality as in urban areas. From designing and manufacturing our own BTS, uniquely developed for the solar-powered rural site, to offering cutting-edge backhaul solutions, we are committed to bringing high quality connectivity to those living in rural and ultra-rural areas.
CONTACT: Jennifer Darcy, [email protected], +44 1908 394482
 

View original content:https://www.prnewswire.co.uk/news-releases/amn-utilises-spacexs-starlink-constellation-to-connect-rural-villages-in-nigeria-302121059.html

Continue Reading

Trending